Thailand’s Medical Services Department signed a 500-million baht deal with MSD (Thailand) today (Thursday) to buy 50,000 courses of Merck’s Molnupiravir (Lagevrio) oral anti-viral medication for the treatment of COVID-19…
Read More
Thailand’s Medical Services Department signed a 500-million baht deal with MSD (Thailand) today (Thursday) to buy 50,000 courses of Merck’s Molnupiravir (Lagevrio) oral anti-viral medication for the treatment of COVID-19…
Read More
Thailand’s cabinet on Tuesday approved the planned purchase of Merck’s Mulnupiravir COVID-19 anti-viral drug, with a budget of 500 million Baht set for 50,000 courses of the drug, amounting to…
Read More
Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by Merck (MRK.N) and Ridgeback Biotherapeutics, in a boost to…
Read More
Thailand is not eligible to produce a generic version of Merck’s Molnupiravir anti-viral drug, which is shown to reduce hospitalisations and deaths among COVID-19 patients by 50%, because it is…
Read More
Thailand’s Centre for COVID-19 Situation Administration (CCSA) today (Thursday) approved the Public Health Ministry’s proposal to procure 50,000 courses of the anti-viral Molnupiravir drug, made by US pharmaceutical company Merck. …
Read More
The Ministry of Public Health is to seek approval from the Thai cabinet for the procurement of 200,000 courses of the Molnupiravir oral anti-viral medicine, using money from the Central…
Read MorePage 1 of 1